Objectives/Goals: To generate phenotype-specific insights that support tailored prevention strategies and advance precision cardiovascular risk management within Gulf health systems. Methods/Study Population: We analyzed collected primary care records and retained 14,616 complete cases. A composite CV risk index was constructed using a Framingham-based general CVD algorithm from standard clinical variables. “High risk” was defined as the top cohort quartile. Between-group differences were tested with the Kruskal–Wallis test followed by Dunn’s multiple comparisons with Benjamini–Hochberg adjustment. We then modeled (i) the binary high-risk outcome using multivariable logistic regression and (ii) the continuous index using linear regression. Adjusted models included body mass index (BMI), log(ESR + 1), log(CRP + 1), and statin use; variables embedded in the index were not re-adjusted to avoid over-adjustment. Results/Anticipated Results: The proportion above the high-index threshold differed by group: RA 29.4%, no autoimmune 25.7%, multiple-autoimmune 23.9%, SLE 19.8%, and Hashimoto’s 12.7%. The Kruskal–Wallis test was significant (H=68.6, df=4, p no autoimmune and SLE, and Hashimoto < all groups. In adjusted logistic regression, odds of high index were higher in RA (OR 1.20, 95% CI 1.06–1.37), lower in Hashimoto (OR 0.49, 95% CI 0.40–0.60), and not clearly different in SLE or multiple-autoimmune. Higher BMI (OR/unit 1.08), ESR (OR/log 1.06), and statin use (OR 4.97) were strongly associated. Discussion/Significance of Impact: In a large primary care cohort, RA showed modestly higher CV risk than non-autoimmune patients after adjustment, while Hashimoto’s showed lower burden. Findings support targeted control of risk factors, especially blood pressure, weight, and inflammation in autoimmune populations.
Al-Hor et al. (Wed,) studied this question.